Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 6:56 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 937–960 of 1,477 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Insulin Dependent Diabetes Mellitus 1 Clear all
Active, not recruiting Phase 2 Interventional

Frexalimab in Preservation of Endogenous Insulin Secretion Compared to Placebo in Adults, Adolescents and Children on Top of Insulin Therapy (FABULINUS)

NCT06111586
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Frexalimab, Placebo, Insulin
Drug
Lead sponsor
Sanofi
Industry
Eligibility
6 Years to 35 Years
Enrollment
197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
14
States / cities
San Francisco, California • Aurora, Colorado • Gainesville, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Oct 16, 2026, 6:56 PM EDT
Completed Early Phase 1 Interventional Results available

Modulation of STAT3 Signaling With Siltuximab in Type 1 Diabetes

NCT02641522
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Siltuximab
Drug
Lead sponsor
Carla Greenbaum, MD
Other
Eligibility
18 Years to 45 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 2, 2018 · Synced Oct 16, 2026, 6:56 PM EDT
Completed Not applicable Interventional

Early Feasibility Study of Zone-MPC and HMS With DiAs in the Outpatient Setting

NCT02463682
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
CGM and Insulin Pump, Closed-Loop Control System
Device
Lead sponsor
Sansum Diabetes Research Institute
Other
Eligibility
21 Years to 65 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
3
States / cities
Santa Barbara, California • Rochester, Minnesota • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 11, 2016 · Synced Oct 16, 2026, 6:56 PM EDT
Completed Phase 3 Interventional

Safety and Efficacy of Insulin Detemir Plus Insulin Aspart Against Insulin Glargine Plus Insulin Aspart as Mealtime Insulin in Type 1 Diabetes

NCT00095082
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 1
Interventions
insulin detemir, insulin glargine, insulin aspart
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
447 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
28
States / cities
Anaheim, California • Huntington Beach, California • Inglewood, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2017 · Synced Oct 16, 2026, 6:56 PM EDT
Completed Phase 1 Interventional Results available

Effect of a Fixed Pramlintide: Insulin Dose Ratio on Postprandial Glucose in Type 1 Diabetes Mellitus

NCT02500979
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Pramlintide acetate, Placebo, Lispro insulin U-100, Regular insulin U-100
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 70 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
3
States / cities
Chula Vista, California • Portland, Oregon • Chattanooga, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 2, 2018 · Synced Oct 16, 2026, 6:56 PM EDT
Completed Not applicable Interventional

Continuous Glucose Monitoring in Women With Type 1 Diabetes in Pregnancy Trial

NCT01788527
View directory record Official record
Conditions
Type 1 Diabetics Who Are Pregnant or Planning Pregnancy
Interventions
CGM
Device
Lead sponsor
Mount Sinai Hospital, Canada
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
325 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Santa Barbara, California
Source: ClinicalTrials.gov public record
Updated Jul 19, 2017 · Synced Oct 16, 2026, 6:56 PM EDT
Completed Phase 2 Interventional Results available

A Study to Investigate the Efficacy and Safety of RG7774 in Patients With Diabetes Mellitus Type 1 or Type 2 With Treatment-Naive Diabetic Retinopathy

NCT04265261
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
Placebo, RG7774
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
37
States / cities
Phoenix, Arizona • Tucson, Arizona • Arcadia, California + 33 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2024 · Synced Oct 16, 2026, 6:56 PM EDT
Completed Phase 1 Interventional

Study to Assess Pharmacodynamics of RM-131 in Patients With Diabetic Gastroparesis

NCT01394055
View directory record Official record
Conditions
Diabetes Mellitus Type 1 and 2, Diabetes Mellitus Complications, Gastroparesis, Gastrointestinal Motility Disorder
Interventions
RM-131, Placebo
Drug
Lead sponsor
Motus Therapeutics, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 22, 2016 · Synced Oct 16, 2026, 6:56 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Telemedicine for Adolescents With Insulin-dependent Diabetes

NCT02155855
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Telemedicine, Control
Other
Lead sponsor
Texas Tech University Health Sciences Center
Other
Eligibility
10 Years to 18 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Lubbock, Texas
Source: ClinicalTrials.gov public record
Updated Dec 10, 2019 · Synced Oct 16, 2026, 6:56 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Study to Investigate Safety and Effectiveness of Porcine Pancreatic Cells (OPF-310) in Patients With Type 1 Diabetes Mellitus

NCT06575426
View directory record Official record
Conditions
Diabetes Mellitus, Type 1, Hypoglycemia, Islet Cell Transplantation, Type 1 Diabetes, Type 1 Diabetes Mellitus, T1D, T1DM, T1DM - Type 1 Diabetes Mellitus, Type 1 Diabetes (T1D), Severe Hypoglycemia, Xenotransplantation, Hypoglycemic Episode, Islet Transplantation in Diabetes Mellitus Type 1, Glucose Metabolism Disorders (Including Diabetes Mellitus), Immune System Diseases, Autoimmune Diseases, Metabolic Disease
Interventions
OPF-310
Combination Product
Lead sponsor
Otsuka Pharmaceutical Factory, Inc.
Industry
Eligibility
35 Years to 70 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 16, 2026, 6:56 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

GPR119 Agonist for Hypoglycemia in Type 1 Diabetes

NCT04432090
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Placebo, Study Medication (MBX-2982), No medication for this group
Drug · Other
Lead sponsor
AdventHealth Translational Research Institute
Other
Eligibility
20 Years to 60 Years
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Oct 17, 2024 · Synced Oct 16, 2026, 6:56 PM EDT
Completed Not applicable Interventional Results available

Closed Loop Control in Adolescents Using Heart Rate as Exercise Indicator

NCT01945060
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
heart rate Control to Range System (hrCTR) using DiAs Platform, DiAs Control-to-Range System not informed for heart rate
Device · Other
Lead sponsor
Marc Breton
Other
Eligibility
12 Years to 17 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
2
States / cities
Charlottesville, Virginia • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 21, 2023 · Synced Oct 16, 2026, 6:56 PM EDT
Withdrawn No phase listed Observational

A Study of Glucose Control in Participants With Type 1 and Type 2 Diabetes

NCT04667182
View directory record Official record
Conditions
Type 1 Diabetes, Type 2 Diabetes
Interventions
Meal-Tagging App and Web-based Portal:, Fitness Tracker
Other · Device
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
25 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
2
States / cities
Boston, Massachusetts • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 17, 2021 · Synced Oct 16, 2026, 6:56 PM EDT
Completed Phase 2 Interventional

Phase 2b Trial Comparing HDV-Insulin Lispro to Insulin Lispro in Adults With Type 1 Diabetes Receiving Insulin Degludec

NCT06238778
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
HDV-Lispro, Lispro
Drug
Lead sponsor
Diasome Pharmaceuticals
Industry
Eligibility
18 Years to 79 Years
Enrollment
227 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
27
States / cities
Huntington Beach, California • Pasadena, California • Tustin, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 16, 2026, 6:56 PM EDT
Not listed Phase 1 Interventional

PK/PD Study of Intranasal Insulin in Type I Diabetes

NCT01201278
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Insulin, Insulin LISPRO
Drug
Lead sponsor
Hompesch, Marcus, M.D.
Individual
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Jun 17, 2011 · Synced Oct 16, 2026, 6:56 PM EDT
Active, not recruiting Not applicable Interventional

Safety and Effectiveness of the Luna System in People With Type 1 Diabetes Mellitus

NCT06627517
View directory record Official record
Conditions
Type 1 Diabetes Mellitus, Sleep Quality
Interventions
Episodic overnight patch pump
Device
Lead sponsor
Luna Diabetes
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
3
States / cities
Walnut Creek, California • Aurora, Colorado • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 27, 2025 · Synced Oct 16, 2026, 6:56 PM EDT
Active, not recruiting Not applicable Interventional

GATEWAY: Safety Evaluation of the MiniMed™ NMX8-AID System in Children and Adults Living With Diabetes

NCT07228117
View directory record Official record
Conditions
Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Interventions
MiniMed™ NMX8-AID System with DS5™/Simplera Sync™
Device
Lead sponsor
Medtronic MiniMed, Inc.
Industry
Eligibility
7 Years to 85 Years
Enrollment
389 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
29
States / cities
Little Rock, Arkansas • Escondido, California • Goleta, California + 25 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 16, 2026, 6:56 PM EDT
Terminated Not applicable Interventional

Control:Diabetes Pilot Study I

NCT04158921
View directory record Official record
Conditions
Insulin Treated Type 2 Diabetes Mellitus, Diabetes Mellitus, Type 1
Interventions
Control:Diabetes mobile app
Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 22, 2023 · Synced Oct 16, 2026, 6:56 PM EDT
Completed Phase 3 Interventional

Six Month Clinical Trial Assessing Efficacy and Safety of Inhaled Insulin in Type 1 Diabetes

NCT00424333
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Inhaled human insulin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years to 65 Years
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2000
U.S. locations
30
States / cities
Duarte, California • Long Beach, California • Los Angeles, California + 27 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2007 · Synced Oct 16, 2026, 6:56 PM EDT
Completed Not applicable Interventional

A Reinforcement Approach to Improve Diabetes Management

NCT02167243
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Reinforcement for BG testing, Standard of care
Behavioral · Other
Lead sponsor
Yale University
Other
Eligibility
12 Years to 21 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 19, 2021 · Synced Oct 16, 2026, 6:56 PM EDT
Completed Phase 2 Interventional

Lactobacillus Johnsonii in Children and Adolescents With T1D

NCT03961854
View directory record Official record
Conditions
Type 1 Diabetes (T1D)
Interventions
L. johnsonii Probiotic, Placebo Capsule
Drug
Lead sponsor
University of Florida
Other
Eligibility
8 Years to 18 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 16, 2026, 6:56 PM EDT
Completed Phase 4 Interventional Results available

Comparison of Insulins Aspart and Lispro in Insulin Pumps

NCT00461331
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Insulin Aspart, Insulin Lispro
Drug
Lead sponsor
Tulane University Health Sciences Center
Other
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Jan 8, 2021 · Synced Oct 16, 2026, 6:56 PM EDT
Completed Phase 2 Interventional Results available

A Study of SIMPONI® to Arrest Beta-cell Loss in Type 1 Diabetes

NCT02846545
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Golimumab, Placebo
Biological
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
6 Years to 21 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
33
States / cities
Little Rock, Arkansas • Newport Beach, California • Sacramento, California + 30 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2025 · Synced Oct 16, 2026, 6:56 PM EDT
Recruiting Phase 1 Interventional

A Single Bolus, 12-hour Euglycemic Clamp Study of the Safety, Pharmacokinetics (PK) and Glucodynamics (GD) of Intraperitoneal (IP) Portal Insulin U-500

NCT07341373
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Portal Insulin U-500, Humulin R U-500, Lyumjev U-100 Insulin
Drug
Lead sponsor
Portal Diabetes, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Oct 16, 2026, 6:56 PM EDT